{
    "clinical_study": {
        "@rank": "1391", 
        "acronym": "IIPOP", 
        "arm_group": [
            {
                "arm_group_label": "Schema B (140\u00b5g)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Schema A (100\u00b5g)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Treatment by association of complete surgical excision of the lesions and intraperitoneal\n      immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis"
        }, 
        "brief_title": "Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab", 
        "completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Gastric Peritoneal Carcinomatosis", 
        "condition_browse": {
            "mesh_term": "Carcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  consent form signed\n\n          -  Age >= 18\n\n          -  Carcinomatosis pre operative known or discivered in intraoperative\n\n          -  Patients uin good general condition who may have extent surgery associated to\n             specific inflammatory syndrom of immunotherapy\n\n          -  Patient insured to social care\n\n        Inclusion Criteria (intraoperative):\n\n          -  Gastric adenocarcinoma with macroscopic peritoneal carcinomatosis (PC) confirmed by\n             extemporaneous histological examination\n\n          -  CP extension minimal or moderate (peritoneal index \u2264 12).\n\n          -  Resection of the entire macroscopic lesions detectable (primary tumor, lymph nodes\n             and CP). cleaning D2 lymph node (or D1.5).\n\n        Exclusion Criteria:\n\n          -  Presence of metastasis in reach\n\n          -  Previous treatment with a non-humanized monoclonal AC- (mice or rat)\n\n          -  Hypersensitivity to any type of antibody.\n\n          -  History of cancer within 5 years preceding the entry in the trial other than basal\n             cell skin carcinoma or in situ of the cervix,\n\n          -  Patients already included in another clinical trial with experimental molecule\n\n          -  Pregnant, or likely to be or breastfeeding, (Women of childbearing potential should\n             have a pregnancy test (blood) negative 15 days before the date of the surgery) Using\n             of a suitable method of contraception for patients of childbearing age during\n             treatment. adequate contraception Methods includeare: an intrauterine device,\n             hormonal contraception, condom use combined with a spermicide\n\n          -  Persons deprived of liberty or Trust (including curatorship)\n\n          -  Unable to undergo medical test for geographical, social or psychological.\n\n        Exclusion Criteria (intraoperative):\n\n          -  Persistent peritoneal lesions visible to the end of the surgery\n\n          -  Resection of the tail of the pancreas or pancreatic break (because no drainage\n             post-op); break pleural (for K cardia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784900", 
            "org_study_id": "2012-000475-17", 
            "secondary_id": "2011/1793"
        }, 
        "intervention": [
            {
                "arm_group_label": "Schema A (100\u00b5g)", 
                "intervention_name": "Catumaxomab 100\u00b5g", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Schema B (140\u00b5g)", 
                "intervention_name": "Catumaxomab 140\u00b5g", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Bispecific"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 5, 2013", 
        "location": {
            "contact": {
                "email": "dominique.elias@igr.fr", 
                "last_name": "ELIAS Dominique, MD", 
                "phone": "142114085", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "cedric.parlavecchio@igr.fr", 
                "last_name": "PARLAVECCHIO Cedric", 
                "phone": "142113465", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Institut Gustave Roussy"
            }, 
            "investigator": {
                "last_name": "ELIAS Dominique, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.", 
        "overall_contact": {
            "email": "dominique.elias@igr.fr", 
            "last_name": "ELIAS Dominique, MD", 
            "phone": "142114085", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "cedric.parlavecchio@igr.fr", 
            "last_name": "PARLAVECCHIO Cedric", 
            "phone": "142113465", 
            "phone_ext": "+33"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "every 3 months for the first two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784900"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5"
        }, 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2012"
    }
}